Bulk Pharmaceutical API Sources for BALVERSA

Bulk Pharmaceutical API Sources for BALVERSA

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-18708
AbaChemScene		CS-4988
ChemShuttle		140492
AbovChem LLC		HY-18708
ZINC		ZINC168520308
AKos Consulting & Solutions		AKOS030526429

BALVERSA Bulk API Sourcing Analysis

Last updated: February 19, 2026

This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sourcing for BALVERSA (erdafitinib). Erdafitinib is an oral fibroblast growth factor receptor (FGFR) inhibitor used in the treatment of certain types of urothelial carcinoma. The availability and cost of bulk API are critical factors influencing manufacturing scalability, market entry timing, and overall profitability for pharmaceutical companies developing or manufacturing products containing erdafitinib.

What is BALVERSA and its Therapeutic Application?

BALVERSA is a once-daily oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has progressed during or after platinum-containing chemotherapy or in patients with an FGFR2 gene fusion or other rearrangement who have progressed after previous T-VEC, an anti-PD-1, or an anti-PD-L1-containing regimen. Its mechanism of action involves inhibiting the activity of FGFRs, which are implicated in the growth and proliferation of cancer cells.

What are the Key Chemical Properties of Erdafitinib?

Erdafitinib is chemically designated as N-[2-[[4-[4-(1-ethoxyethyl)-1H-1,2,4-triazol-5-yl]phenyl]amino]-5-methoxyphenyl]-4-(methylsulfonyl)benzamide. Its molecular formula is C26H29N5O5S, and it has a molecular weight of 523.60 g/mol. The compound is typically a solid under ambient conditions. Understanding these properties is crucial for API manufacturing, as it dictates synthesis routes, purification methods, and stability considerations during storage and transport.

Who are the Primary API Manufacturers for Erdafitinib?

The primary manufacturers of bulk erdafitinib API are typically specialized contract development and manufacturing organizations (CDMOs) or in-house manufacturing operations of the originator company. Identification of specific API suppliers often involves reviewing patent filings, regulatory submissions (e.g., Drug Master Files or DMFs), and supply chain intelligence reports. As of the latest available data, key players in advanced pharmaceutical intermediate and API manufacturing with capabilities for complex small molecules like erdafitinib include:

• Lonza: A global CDMO with extensive experience in small molecule synthesis and regulatory compliance.
• Catalent: Offers integrated services from development to commercial manufacturing of APIs.
• WuXi AppTec: A leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
• Dr. Reddy's Laboratories: A significant player in the generic and proprietary API space.
• Piramal Pharma Solutions: Provides integrated services from drug discovery to commercial manufacturing.

Specific supply agreements and manufacturing sites are often proprietary and not publicly disclosed. However, these companies represent the typical scale and technological expertise required for erdafitinib API production.

What are the Patent Landscape and Exclusivity Periods for Erdafitinib API?

The patent landscape for erdafitinib is critical for understanding API sourcing. Patents protect the composition of matter, methods of synthesis, and specific polymorphic forms of the API.

• Composition of Matter Patent: The primary patent covering erdafitinib itself would have been filed upon discovery. For instance, U.S. Patent No. 8,841,318, titled "Pyrazolopyrimidine compounds," lists erdafitinib and its therapeutic uses. This patent, and its corresponding international filings, are fundamental to exclusivity.
• Manufacturing Process Patents: Separate patents often cover novel or improved synthetic routes to the API. These can provide additional layers of protection and influence the cost and accessibility of the API by competitors once the primary patents expire. An example might be patents detailing specific crystallization techniques or chiral separation methods.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can affect bioavailability and manufacturing. Patents covering specific, stable, and therapeutically relevant polymorphs are common and can extend market exclusivity.
• Exclusivity Periods: The duration of patent protection varies by jurisdiction, typically lasting 20 years from the filing date, subject to potential extensions (e.g., Patent Term Extension in the U.S.) to compensate for regulatory review delays.
  • For erdafitinib, initial patent filings likely occurred in the late 2000s or early 2010s.
  • The U.S. Patent 8,841,318 was filed on March 28, 2014, and issued on September 23, 2014.
  • The expiration of key composition of matter patents for erdafitinib will significantly impact the availability of generic APIs. Based on a 2014 filing date, primary patent expiration would be in 2034, without considering any extensions.
  • Regulatory exclusivities granted by agencies like the FDA (e.g., New Chemical Entity or NCE exclusivity) also provide market protection separate from patents. BALVERSA received FDA approval on April 12, 2019, granting it 5 years of NCE exclusivity, which would expire in April 2024. This exclusivity period relates to the drug product, not directly to the API manufacturing freedom of generic companies, but it delays the introduction of generic drug products.

What are the Regulatory Requirements for API Sourcing?

Sourcing API for a globally marketed drug like BALVERSA necessitates strict adherence to regulatory standards.

• Good Manufacturing Practices (GMP): API manufacturers must comply with current GMP (cGMP) regulations set forth by regulatory bodies such as the FDA, European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This ensures consistent quality, purity, and potency of the API.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Pharmaceutical companies referencing a DMF in their drug applications (e.g., an Abbreviated New Drug Application or ANDA for generics) can ensure the API meets regulatory standards without needing to disclose proprietary manufacturing details.
• Impurity Profiling: Rigorous control and characterization of process-related impurities and degradation products are mandatory. Limits for specific impurities are established based on toxicological data and regulatory guidelines (e.g., ICH Q3A/B).
• Stability Studies: Comprehensive stability data demonstrating the API's quality over its proposed shelf life under various storage conditions are required.

What are the Critical Quality Attributes (CQAs) for Erdafitinib API?

CQAs are the physical, chemical, biological, or microbiological attributes of a product that should be within an appropriate limit, range, or distribution to ensure the desired product quality. For erdafitinib API, key CQAs include:

• Assay: Minimum acceptable percentage of erdafitinib. Typically >98.5% or higher.
• Related Substances/Impurities: Limits on specific known impurities and unspecified impurities. Often expressed as a percentage of the API. For example, limits might be set for stereoisomers, residual starting materials, or synthesis byproducts. (e.g., Individual unspecified impurity <0.10%, Total impurities <1.0%).
• Residual Solvents: Limits for solvents used during synthesis and purification, as defined by ICH Q3C guidelines. (e.g., Methanol <3000 ppm, Ethanol <5000 ppm).
• Water Content: Maximum allowable percentage of water. (e.g., <0.5%).
• Heavy Metals: Limits for heavy metal contamination. (e.g., <10 ppm).
• Particle Size Distribution (PSD): Important for dissolution rate and manufacturability of the final dosage form. Specific ranges may be defined based on formulation requirements.
• Polymorphic Form: Confirmation of the intended crystalline form is critical for consistent bioavailability and stability.
• Chiral Purity: If stereoisomers exist and have different pharmacological profiles, strict control over chiral purity is essential.

What are the Potential Challenges in Bulk API Sourcing?

Sourcing bulk erdafitinib API presents several challenges:

• Complex Synthesis Route: The multi-step synthesis of erdafitinib likely involves specialized reagents and reaction conditions, increasing manufacturing complexity and cost.
• Intellectual Property: Existing patents on synthesis routes or polymorphic forms can restrict the number of qualified manufacturers or necessitate licensing agreements.
• Scale-Up: Transitioning from laboratory scale to commercial-scale API production requires significant investment in specialized equipment and process optimization.
• Quality Control: Maintaining consistent high quality across multiple batches and potentially multiple manufacturing sites is a continuous challenge.
• Supply Chain Security: Ensuring a reliable and uninterrupted supply chain, especially for critical raw materials used in erdafitinib synthesis, is paramount. Geopolitical instability, natural disasters, or single-source dependencies can create vulnerabilities.
• Cost Management: Balancing the need for high-quality, regulatory-compliant API with cost-effectiveness is crucial, particularly for the generic market.

What are the Economic Considerations for API Sourcing?

The economic factors influencing erdafitinib API sourcing are multifaceted:

• Manufacturing Cost: This includes raw material costs, labor, energy, waste disposal, quality control, and capital investment in facilities and equipment.
• Regulatory Compliance Costs: Costs associated with maintaining GMP standards, validation studies, and dossier preparation (DMFs).
• Supply Volume: The required volume of API significantly impacts per-unit cost due to economies of scale. Large-volume contracts generally secure lower per-kilogram pricing.
• Lead Times: Longer lead times for API production can impact market entry and inventory management, incurring holding costs.
• Geographic Location of Manufacturers: Manufacturing costs can vary significantly based on the geographic region, influenced by labor rates, regulatory stringency, and raw material availability. Asia, particularly China and India, often offers competitive pricing for API manufacturing.
• Generic Competition: The impending expiration of patents and regulatory exclusivities will lead to increased demand from generic manufacturers, potentially driving down API prices through market competition.

Key Takeaways

Bulk erdafitinib API sourcing is governed by stringent regulatory requirements, complex intellectual property rights, and significant manufacturing challenges. Manufacturers must ensure adherence to cGMP, manage impurity profiles, and secure reliable supply chains. Key API suppliers are specialized CDMOs with expertise in complex small molecule synthesis. The patent landscape, with primary composition of matter patents likely expiring in the mid-2030s, will shape future market dynamics, including the entry of generic APIs. Critical Quality Attributes for erdafitinib API include assay, impurity levels, residual solvents, and polymorphic form. Economic considerations revolve around manufacturing costs, regulatory compliance, supply volume, and the evolving competitive landscape.

Frequently Asked Questions

What is the estimated typical lead time for a commercial batch of erdafitinib API from a qualified manufacturer?

Commercial batch lead times for complex small molecule APIs typically range from 4 to 9 months, encompassing process validation, batch execution, and quality release testing. This period can vary based on the manufacturer's existing capacity, raw material availability, and the complexity of the specific synthesis route.

Are there specific polymorphic forms of erdafitinib that are protected by patents and critical for sourcing?

Yes, it is common for pharmaceutical companies to patent specific crystalline forms (polymorphs) of an API if they offer advantages in stability, solubility, or manufacturability. Sourcing strategies must consider whether the intended polymorphic form is subject to patent protection, which could necessitate licensing or the development of alternative, non-infringing forms.

What are the primary risks associated with single-source API manufacturing for erdafitinib?

The primary risks of single-source API manufacturing include supply chain disruptions due to manufacturing issues, quality deviations, natural disasters, or geopolitical events. This can lead to stock-outs, production delays, and significant financial losses. It also reduces negotiation leverage regarding pricing and contract terms.

How does the cost of erdafitinib API compare to other FGFR inhibitors currently on the market?

Direct cost comparisons are difficult without specific supplier pricing data, which is highly proprietary. However, the cost of erdafitinib API is likely influenced by the complexity of its multi-step synthesis, the proprietary nature of its manufacturing process, and the scale of production. Generally, highly targeted kinase inhibitors with complex molecular structures tend to have higher API manufacturing costs compared to simpler molecules.

What is the role of a Drug Master File (DMF) in sourcing erdafitinib API from international manufacturers?

A Drug Master File (DMF) is a submission to a regulatory authority (like the FDA) that provides confidential, detailed information about the manufacturing, processing, packaging, and storing of an API. When sourcing erdafitinib API from an international manufacturer, a DMF allows a drug product applicant to reference the manufacturer's API information in their own regulatory filing without the API manufacturer directly disclosing proprietary details to the applicant. This streamlines the regulatory review process and ensures the API meets quality and safety standards.

Citations

[1] U.S. Patent No. 8,841,318. (2014). Pyrazolopyrimidine compounds. United States Patent and Trademark Office. [2] U.S. Food and Drug Administration. (2019). BALVERSA Prescribing Information. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Impurities in New Drug Substances Q3A(R2). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Impurities in New Drug Products Q3B(R2). [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019). ICH Harmonised Guideline Impurities: Guideline for Residual Solvents Q3C(R8).